Since its introduction on Euronext Brussels in December 2002, the volume of share transactions in Innogenetics on NASDAQ Europe has gradually decreased. It was therefore decided by the Company's Board of Directors that a voluntary de- listing should be sought.
Chief Executive Officer, Philippe Archinard, commented: "Today, the majority of Innogenetics shares are traded on the Euronext trading platform. We decided to opt for a de-listing from NASDAQ Europe because of the limited added value to our shareholders and the cost of maintaining a dual listing."
Innogenetics shares will cease to trade on NASDAQ Europe at the close of business on August 15, 2003. Following the de-listing and consolidation of Innogenetics shares, its existing shareholders will not have to take any action to transfer their shareholdings. Importantly, they will not incur any additional costs as a result of the de-listing and can continue to trade Innogenetics shares on the Euronext Brussels stock market.
Innogenetics will continue to provide its shareholders with quarterly press releases, publications and other information on http://www.innogenetics.com and on the Euronext website at http://www.euronext.be.
